nab-Paclitaxel and Carboplatin

Phase 3Small molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

nab-Paclitaxel and Carboplatin is one of 24 small molecule programs targeting Neoadjuvant Chemotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant ChemotherapyNot yet recruiting

Neoadjuvant ChemotherapyPhase 3

Not yet recruiting

Competition

Competitive Landscape

27 competitors in Neoadjuvant Chemotherapy

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

6 2

Taxol

Teva

Phase 3

5 3

Eloxatin

Teva

Phase 3

4 4

Keytruda

Merck & Co.

Phase 3

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 6

Abraxane

Bristol-Myers Squibb

Phase 2

3 7

Adriamycin

Pfizer

Phase 2

3 8

Neoadjuvant Chemotherapy

JJapan Clinical Oncology Group

Phase 3

6 9

Beyfortus

BeiGene

Phase 2

2 10

Tecentriq

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2/3Not yet recruiting

Neoadjuvant Chemotherapy

NCT07463313

Clinical

Trials by Indication[1]

Neoadjuvant Chemotherapy1 trial

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2/3·NCT07463313·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nab-Paclitaxel and Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nab-Paclitaxel and Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nab-Paclitaxel and Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

nab-Paclitaxel and Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Neoadjuvant Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News